Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boehringer Ingelheim’s pimobendan

Executive Summary

Company is seeking outlicensing agreement or development partnership for the oral positive inotropic drug treatment for congestive heart failure. Decision is based on the "considerable resources" needed to develop drugs in this class to meet U.S. approval requirements, which "would have conflicted" with other "priority projects" in its pipeline, company explains in a March 9 announcement. If no agreement is reached, B-I will halt development of the drug, which is in Phase III.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS020540

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel